<snip>
Stem cell research and diabetes
February 2002 (Reviewed April 2006)
Since its inception in 1934, Diabetes UK has supported a wide range of research aimed at finding a cure and improving the care and prevention of diabetes and its complications.
Stem cell research is a relatively new area of investigation, believed by many in the scientific and medical communities to have important new potential for the treatment of many diseases and conditions particularly those like diabetes, which are characterised by severe damage to certain cells and tissues. We cannot know what benefits any particular avenue of research may yield in the long term. The potential of human stem cell research is that it could lead to the identification of the pathway that results in the production of functioning, insulin-producing islet cells. This could provide potentially limitless supplies of islet cells to become available for transplantation (see below for more information).
It could also become a source of kidney, nerve and heart muscle cells for people whose organs have been damaged by the complications of diabetes. There are important ethical issues concerning stem cell research, in particular about the use of stem cells derived from early human embryos (pre-14 days old). Some people oppose the research on ethical grounds.
Following wide-ranging consultation with members about the ethical issues, Diabetes UK’s Board of Trustees, has agreed to support stem cell research both publicly, and financially through our research grant programme. In making their decision the Trustees paid respectful attention to all the arguments and took into consideration the views of people living with diabetes. Our consultation activities indicated that almost all people living with diabetes approved the continuation of carefully regulated and monitored stem cell research and an overwhelming majority favoured the use of embryonic stem cells. The Trustees gave consideration to concerns about cell nuclear replacement and the question of whether the research should be confined to embryos left over from in-vitro fertilisation treatment (IVF), and not involve the creation of new embryos.
<more>
http://www.diabetes.org.uk/infocentre/state/stemcell.htm